Your session is about to expire
← Back to Search
Glaucoma Implant
AqueSys XEN 45 Glaucoma Implant for Glaucoma
N/A
Waitlist Available
Research Sponsored by AqueSys, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
Study Summary
To establish the safety and performance of the AqueSys XEN 45 Glaucoma Implant in eyes with refractory glaucoma.
Eligible Conditions
- Glaucoma
- Open-Angle Glaucoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Mean Change in IOP From Baseline
Proportion of Subjects Achieving a 20% or Greater Reduction in IOP From Baseline on the Same or Less Number of Medications
Trial Design
1Treatment groups
Experimental Treatment
Group I: AqueSys XEN 45 Glaucoma ImplantExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AqueSys XEN 45 Glaucoma Implant
2013
N/A
~70
Find a Location
Who is running the clinical trial?
AqueSys, Inc.Lead Sponsor
2 Previous Clinical Trials
259 Total Patients Enrolled
2 Trials studying Glaucoma
259 Patients Enrolled for Glaucoma
AllerganIndustry Sponsor
781 Previous Clinical Trials
276,766 Total Patients Enrolled
91 Trials studying Glaucoma
49,051 Patients Enrolled for Glaucoma
Richard A Lewis, M.D.Study ChairGrutzmacher, Lewis & Sierra Surgical Eye Specialists
1 Previous Clinical Trials
60 Total Patients Enrolled
1 Trials studying Glaucoma
60 Patients Enrolled for Glaucoma
Share this study with friends
Copy Link
Messenger